Skip to main content

Table 1 Studies evaluating the economic impact of misdiagnosing BD as MDD, as represented by mean annual per-patient costs

From: Using decision-analysis modelling to estimate the economic impact of the identification of unrecognised bipolar disorder in primary care: the untapped potential of screening

Added annual cost of misdiagnosis studies
Study N Year of collection Correctly diagnosed Misdiagnosed Relative costs
RBP MDD UBP UBP vs. RBP UBP vs. MDD
Li et al. (2002)* 3349 1994–1999 $5044
Shi et al. (2004)* 25,460 1993–1999 $682 $995
Matza et al. (2005) 2307 2000 $8600 $7288 $8761 $161 $1373
Birnbaum et al. (2003) 9009 1998–2001 $9612 $7020 $14,148 $4536 $7128
McCombs et al. (2007)* 14,809 1993–2004 $2316 $1681
  1. Relative costs show the difference in costs between correctly diagnosed patients and UBP. Reported costs reflect values as published in the respective studies and have not been adjusted for inflation. N: Sample size; BD: Bipolar disorder; MDD: Major depressive disorder; RBP: Recognised bipolar disorder patients; UBP: Unrecognised bipolar disorder patients
  2. *Studies using Medi-Cal data